eureKARE is a unique project development company dedicated to investing and developing next generation biotechnology companies in the cutting-edge fields of the microbiome and synthetic biology.

 

Background

  • A pioneering new company focused on financing and building next generation biotechnology companies in the disruptive fields of the microbiome and synthetic biology
  • The company launched with a $60 million Series A and investments in three novel companies

 

Strategy

  • Development and refinement of key corporate materials, including key messages, press release, Q&A, website, corporate presentation, and social media strategy and content
  • Strategic targeting of international business and specialist industry media under embargo

 

Outcome

  • Successful company launch garnering a significant amount of interest from key stakeholders
  • Extensive coverage across key publications including The Wall Street Journal, Fierce Biotech, Endpoints, Scrip, BioWorld, Dow Jones and French national media
  • Strong social media launch campaign resulting in increased engagement and impressions